These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 24004437)

  • 1. Economic burden of selected adverse events in patients aged ≥65 years with metastatic renal cell carcinoma.
    Hagiwara M; Hackshaw MD; Oster G
    J Med Econ; 2013 Nov; 16(11):1300-6. PubMed ID: 24004437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic burden of adverse events in patients with metastatic renal cell carcinoma.
    Hagiwara M; Borker R; Oster G
    Clin Ther; 2013 Dec; 35(12):1955-1963.e2. PubMed ID: 24290735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Costs associated with adverse events in patients with metastatic renal cell carcinoma.
    Borker R
    J Med Econ; 2014 Nov; 17(11):792-7. PubMed ID: 25116694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and Economic Outcomes in Elderly Advanced Renal Cell Carcinoma Patients Starting Pazopanib or Sunitinib Treatment: A Retrospective Medicare Claims Analysis.
    Vogelzang NJ; Pal SK; Ghate SR; Swallow E; Li N; Peeples M; Zichlin ML; Meiselbach MK; Perez JR; Agarwal N
    Adv Ther; 2017 Nov; 34(11):2452-2465. PubMed ID: 29076108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-World Economic Outcomes During Time on Treatment Among Patients Who Initiated Sunitinib or Pazopanib as First Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Analysis of Medicare Claims Data.
    Vogelzang NJ; Pal SK; Ghate SR; Li N; Swallow E; Peeples M; Zichlin ML; Meiselbach MK; Perez JR; Agarwal N
    J Manag Care Spec Pharm; 2018 Jun; 24(6):525-533. PubMed ID: 29799328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of adverse events of targeted therapies in normal and special patients with metastatic renal cell carcinoma.
    Méndez-Vidal MJ; Martínez Ortega E; Montesa Pino A; Pérez Valderrama B; Viciana R
    Cancer Metastasis Rev; 2012 Sep; 31 Suppl 1():S19-27. PubMed ID: 22821550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic evaluation of everolimus versus sorafenib for the treatment of metastatic renal cell carcinoma after failure of first-line sunitinib.
    Casciano R; Chulikavit M; Di Lorenzo G; Liu Z; Baladi JF; Wang X; Robertson J; Garrison L
    Value Health; 2011; 14(6):846-51. PubMed ID: 21914504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strategies for assessing and managing the adverse events of sorafenib and other targeted therapies in the treatment of renal cell and hepatocellular carcinoma: recommendations from a European nursing task group.
    Edmonds K; Hull D; Spencer-Shaw A; Koldenhof J; Chrysou M; Boers-Doets C; Molassiotis A
    Eur J Oncol Nurs; 2012 Apr; 16(2):172-84. PubMed ID: 21641280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: effectiveness, safety and treatment patterns in clinical practice-based on medical chart review.
    Choueiri TK; Duh MS; Clement J; Brick AJ; Rogers MJ; Kwabi C; Shah K; Percy AG; Antràs L; Jayawant SS; Chen K; Wang ST; Luka A; Neary MP; McDermott D; Oh WK
    BJU Int; 2010 May; 105(9):1247-54. PubMed ID: 19863525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pazopanib for the treatment of metastatic renal cell carcinoma.
    Pick AM; Nystrom KK
    Clin Ther; 2012 Mar; 34(3):511-20. PubMed ID: 22341567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost implications of IV versus oral anti-angiogenesis therapies in patients with advanced renal cell carcinoma: retrospective claims database analysis.
    Duh MS; Dial E; Choueiri TK; Fournier AA; Antras L; Rodermund D; Neary MP; Oh WK
    Curr Med Res Opin; 2009 Aug; 25(8):2081-90. PubMed ID: 19586325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An indirect comparison of the toxicity of sunitinib and pazopanib in metastatic clear cell renal cancer.
    Powles T; Sarwar N; Jones R; Wilson P; Boleti E; Protheroe A; Crabb SJ; Shamash J; Stockdale A; Rashid S; Nathan P; Chowdury S
    Eur J Cancer; 2012 Nov; 48(17):3171-6. PubMed ID: 22766517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patterns of Care in Patients with Metastatic Renal Cell Carcinoma Among a U.S. Payer Population with Commercial or Medicare Advantage Membership.
    Miller LA; Stemkowski S; Saverno K; Lane DC; Tao Z; Hackshaw MD; Loy B
    J Manag Care Spec Pharm; 2016 Mar; 22(3):219-26. PubMed ID: 27003551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pazopanib has equivalent anti-tumor effectiveness and lower Total costs than Sunitinib for treating metastatic or advanced renal cell carcinoma: a meta-analysis.
    Deng H; Huang Y; Hong Z; Yuan X; Cao Z; Wei Y; Zhang W
    BMC Cancer; 2019 May; 19(1):489. PubMed ID: 31122210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Burden of venous leg ulcers in the United States.
    Rice JB; Desai U; Cummings AK; Birnbaum HG; Skornicki M; Parsons N
    J Med Econ; 2014 May; 17(5):347-56. PubMed ID: 24625244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutropenia-related costs in patients treated with first-line chemotherapy for advanced non-small cell lung cancer.
    Stokes ME; Muehlenbein CE; Marciniak MD; Faries DE; Motabar S; Gillespie TW; Lipscomb J; Knopf KB; Buesching DP
    J Manag Care Pharm; 2009 Oct; 15(8):669-82. PubMed ID: 19803556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world treatment patterns and adverse events in metastatic renal cell carcinoma from a large US claims database.
    Pal S; Gong J; Mhatre SK; Lin SW; Surinach A; Ogale S; Vohra R; Wallen H; George D
    BMC Cancer; 2019 Jun; 19(1):548. PubMed ID: 31174493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of high cost sharing and targeted therapy initiation among elderly Medicare patients with metastatic renal cell carcinoma.
    Li P; Wong YN; Jahnke J; Pettit AR; Doshi JA
    Cancer Med; 2018 Jan; 7(1):75-86. PubMed ID: 29195016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sorafenib rechallenge in patients with metastatic renal cell carcinoma.
    Nozawa M; Yamamoto Y; Minami T; Shimizu N; Hatanaka Y; Tsuji H; Uemura H
    BJU Int; 2012 Sep; 110(6 Pt B):E228-34. PubMed ID: 22332735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sorafenib for the treatment of advanced renal cell carcinoma.
    Kane RC; Farrell AT; Saber H; Tang S; Williams G; Jee JM; Liang C; Booth B; Chidambaram N; Morse D; Sridhara R; Garvey P; Justice R; Pazdur R
    Clin Cancer Res; 2006 Dec; 12(24):7271-8. PubMed ID: 17189398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.